title: Synthetic DNA approach to cytomegalovirus vaccine/immune therapy.
abstract: There is no licensed vaccine or cure for human cytomegalovirus (CMV), a ubiquitous β-herpes virus that infects 60-95 % of adults worldwide. Infection is a major cause of congenital abnormalities in newborns, contributes to development of childhood cerebral palsy and medulloblastoma, can result in severe disease in immunocompromised patients, and is a major impediment during successful organ transplantation. While CMV has been increasingly associated with numerous inflammatory diseases and cancers, only recently has it been correlated with increased risk of heart disease in adults, the number-one killer in the USA. These data, among others, suggest that subclinical CMV infection, or microinfection, in healthy individuals may play more of a causative role than an epiphenomenon in development of CMV-associated pathologies. Due to the myriad of diseases and complications associated with CMV, an efficacious vaccine would be highly valuable in reducing human morbidity and mortality as well as saving billions of dollars in annual health-care costs and disability adjusted life years (DALY) in the developing world. Therefore, the development of a safe efficacious CMV vaccine or immune therapy is paramount to the public health. This review aims to provide a brief overview on aspects of CMV infection and disease and focuses on current vaccine strategies. The use of new synthetic DNA vaccines might offer one such approach to this difficult problem.
authors.affiliation: Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, 505A Stellar-Chance Laboratories Curie Blvd, Philadelphia, 19104, PA, USA.
authors.forename: Stephan J
authors.initials: SJ
authors.lastname: Wu
authors.forename: Daniel O
authors.initials: DO
authors.lastname: Villarreal
authors.forename: Devon J
authors.initials: DJ
authors.lastname: Shedlock
authors.forename: David B
authors.initials: DB
authors.lastname: Weiner
mesh_terms: D000328:Adult; D000818:Animals; D003001:Cloning, Molecular / Q000379:methods*; D003587:Cytomegalovirus / Q000235:genetics / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D022482:Cytomegalovirus Vaccines / Q000235:genetics / Q000627:therapeutic use*; D004274:DNA, Recombinant / Q000235:genetics / Q000627:therapeutic use; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D019444:Vaccines, DNA / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D022482:Cytomegalovirus Vaccines; D004274:DNA, Recombinant; D019444:Vaccines, DNA